natgillin/translations-raw huggingface dataset:
The degree and duration of aPTT normalisation observed after administration of Helixate NexGen is similar to that achieved with plasma-derived factor VIII.
Stopnja in trajanje normalizacije APTČ sta pri zdravilu Helixate NexGen podobna kot pri faktorju VIII, ki je pridobljen iz plazme.
The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency.
Stopnja kopičenja desloratadina je v skladu z razpolovnim časom zdravila (približno 27 ur) in pogostnostjo odmerjanja – enkrat na dan.
The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency.
Stopnja kopičenja desloratadina se sklada z njegovim razpolovnim časom (približno 27 ur) in uporabo enkrat na dan.
The degree of dizziness, sleepiness and decreased concentration may be increased if Pregabalin Sandoz GmbH is taken together with medicinal products containing:
Omotica, zaspanost ali zmanjšanje sposobnosti koncentracije se lahko stopnjujejo, če zdravilo Pregabalin Sandoz GmbH vzamemo skupaj z zdravili, ki vsebujejo:
The degree of dizziness, sleepiness and decreased concentration may be increased if Pregabalin Sandoz is taken together with medicinal products containing:
Omotica, zaspanost ali zmanjšanje sposobnosti koncentracije se lahko stopnjujejo, če zdravilo Pregabalin Sandoz vzamemo skupaj z zdravili, ki vsebujejo:
The degree of reduction is likely to be clinically significant (see section 4.5).
Verjetno je, da je velikost zmanjšanja klinično pomembna (glejte poglavje 4.5).
The degree of renal impairment was defined according to baseline creatinine clearance (CrCl) (normal renal function when CrCl > 80 ml/min; mild impairment with CrCl = 50 – 79 ml/min; moderate impairment with CrCl = 30 – 49 ml/min and severe impairment with CrCl = 10 – 29 ml/min).
Stopnja ledvične okvare je bila določena glede na začetno vrednost očistka kreatinina (ClCr) (normalna ledvična funkcija je pri ClCr > 80 ml/min; blaga ledvična okvara pri ClCr = 50-79 ml/min; zmerna ledvična okvara pri ClCr = 30-49 ml/min in huda ledvična okvara pri ClCr = 10- 29 ml/min).
The degree of renal impairment was defined according to baseline creatinine clearance (CrCL) (normal renal function when CrCL > 80 mL/min; mild impairment with CrCL = 50-79 mL/min; moderate impairment with CrCL = 30-49 mL/min and severe impairment with CrCL = 10-29 mL/min).
Stopnja ledvične okvare je bila določena glede na začetno vrednost očistka kreatinina (CLCr) (normalna ledvična funkcija je pri CLCr > 80 ml/min; blaga ledvična okvara pri CLCr = 50-79 ml/min; zmerna ledvična okvara pri CLCr = 30-49 ml/min in huda ledvična okvara pri CLCr = 10-29 ml/min).
The degree of variation between individual patients and between laboratory assays of CD34+ cells mean that direct comparison between different studies is difficult.
Stopnja variabilnosti med posameznimi bolniki in med laboratorijskimi preverjanji celic CD34+ pomeni, da je neposredna primerjava med različnimi študijami težka.
The degrees of interaction mentioned below are not absolute values and may be dependent on the ketoconazole dose given i.e. many results are reported following a ketoconazole dose of 200 mg and a stronger interaction may be expected at a higher dose and/or shorter dosing interval.
Stopnje spodaj navedenih interakcij niso absolutne vrednosti in so lahko odvisne od odmerka ketokonazola, tj. o mnogih rezultatih so poročali po odmerku ketokonazola 200 mg, zato se lahko pri večjem odmerku in/ali krajšem presledku odmerjanja pričakuje močnejša interakcija.
The delay in the introduction or removal of a catheter does not ensure that the intramedullary haematoma does not occur.
Odložitev namestitve ali odstranitve katetra še ni zagotovilo, da se intramedularni hematom ne pojavi.
The delay of gastric emptying with lixisenatide may reduce the rate of absorption of orally administered medicinal products.
Upočasnitev praznjenja želodca zaradi liksisenatida lahko vpliva na absorpcijo peroralno uporabljenih zdravil.
The delay of gastric emptying with lixisenatide may reduce the rate of absorption of orally administered medicinal products.
Upočasnitev praznjenja želodca zaradi liksisenatida lahko zmanjša absorpcijo peroralno uporabljenih zdravil.
The demographic and disease characteristics of the overall study population were 62% female, median age of 53 years, baseline Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (95%), 51% White and 46% Asian, 4% current smokers, 32% past smokers and 64% never smokers.
Demografske značilnosti in značilnosti bolezni v celotni študijski populaciji so bile naslednje: 62 % ženski spol, mediana starosti 53 let, izhodiščno telesno stanje po ECOG (Eastern Cooperative Oncology Group) 0 ali 1 (95 %), 51 % belopolti in 46 % Azijci, 4 % trenutni kadilci, 32 % nekdanji kadilci in 64 % bolniki, ki niso nikoli kadili.
The demographic and disease characteristics were 50% female, median age of 51 years, baseline ECOG performance status of 0 (32%) or 1 (55%), 61% White and 30% Asian, less than 1% were current smokers, 27% former smokers, 72% never smokers, 94% metastatic, and 98% of the cancers were classified as adenocarcinoma histology.
Demografske značilnosti in značilnosti bolezni so bile naslednje: 50 % žensk, mediana starosti 51 let, izhodiščno stanje zmogljivosti po ECOG 0 (32 %) ali 1 (55 %), 61 % belcev in 30 % Azijcev, manj kot 1 % trenutnih kadilcev, 27 % nekdanjih kadilcev in 72 % bolnikov, ki niso nikoli kadili, metastatska bolezen pri 94 % bolnikov, 98 % tumorjev je bilo histološko razvrščenih med adenokarcinome.
The demographic and disease characteristics were 57% female, median age of 53 years, baseline ECOG performance status of 0/1 (82%) or 2/3 (18%), 52% White and 44% Asian, 4% current smokers, 30% former smokers, 66% never smokers, 92% metastatic, and 94% of the cancers were classified as adenocarcinoma histology.
Demografske značilnosti in značilnosti bolezni so bile naslednje: 57 % žensk, mediana starosti 53 let, izhodiščno stanje zmogljivosti po ECOG 0/1 (82 %) ali 2/3 (18 %), 52 % belcev in 44 % Azijcev, 4 % trenutnih kadilcev, 30 % nekdanjih kadilcev, 66 % bolnikov, ki niso nikoli kadili, metastatska bolezen pri 92 % bolnikov in 94 % tumorjev histološko razvrščenih med adenokarcinome.
The demographic characteristics of the T790M positive study population (n=63) were median age 60 years, female (62%), White (35%), Asian (59%), World Health Organization (WHO) performance status of 0 or 1 (100%) and never smokers (67%).
Demografske značilnosti T790M-pozitivne študijske populacije (n = 63) so bile: mediana starost 60 let, 62 % žensk, 35 % belcev, 59 % Azijcev, zmogljivost po Svetovni zdravstveni organizaciji 0 ali 1 (100 %); 67 % bolnikov ni nikoli kadilo.
The demographic characteristics were 57% female; median age 55 years; baseline ECOG performance status of 0 or 1 (98%) or 2 (2%), 57% White and 40% Asian; 25% former smokers, and 75% never smokers.
Demografske značilnosti so bile naslednje: 57 % žensk, mediana starosti 55 let, izhodiščno stanje zmogljivosti po ECOG 0 ali 1 (98 %) ali 2 (2 %), 57 % belcev in 40 % Azijcev, 25 % nekdanjih kadilcev in 75 % bolnikov, ki niso nikoli kadili.
The demographic data and baseline characteristics were well balanced (median age 63 years, the majority were Caucasian [88%] and male [58%]).
Demografski podatki in izhodiščne značilnosti so bili dobro uravnoteženi (mediana starost 63 let, večina je bila belcev [88 %] in moških [58 %]).
The demographics and baseline characteristics for study 2011-003 were well-balanced between the two arms, including prior treatment with bortezomib (54%), prior treatment with lenalidomide (38%), lenalidomide refractory (25%), age (65 years, range 30-89 years), gender (51% male), ECOG performance status (45% with performance status 1), high-risk genetic mutations, consisting of the genetic subtypes t(4;14), t(14;16), or deletion 17p in ≥ 60% of plasma cells (23%) unknown-risk genetic mutations, which included subjects with results not collected or not analysed (9%) and baseline ISS stage III disease (24%).
Demografske in izhodiščne značilnosti v študiji 2011-003 so bile med skupinama dobro uravnotežene, vključno s predhodnim zdravljenjem z bortezomibom (54 %), predhodnim zdravljenjem z lenalidomidom (38 %), odpornostjo na lenalidomid (25 %), starostjo (65 let, razpon od 30 do 89 let), spolom (51 % moških), stanjem zmogljivosti po ECOG (45 % s stanjem zmogljivosti 1), visoko tveganimi genetskimi mutacijami, ki so obsegale genetske podvrste t(4;14), t(14;16) ali delecijo 17p pri ≥ 60 % plazmatk (23 %), genetskimi mutacijami z neznanim tveganjem, ki so obsegale bolnike z neodvzetimi ali neanaliziranimi vzorci (9 %) in izhodiščno III. stadijem bolezni po ISS (24 %).
The demographics data and baseline characteristics were well balanced between the treatment groups.
Demografski podatki in izhodiščne značilnosti so bili med skupinama dobro uravnoteženi.
The demonstrated duration of immunity protects the birds during the period when they are most susceptible to Muscovy duck parvovirosis and Derzsy’s disease.
Trajanje imunosti zaščiti ptice v starostnem obdobju, ko so najbolj dovzetne za okužbo s parvovirusom rac moškatnih bleščavk in Derzsyjevo bolezen.
The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).
Koristi zdravljenja z zdravilom Karvea za ledvice pri bolnikih z visokim krvnim tlakom z diabetesom tipa 2 so pokazale študije, kjer so irbesartan uporabljali dodatno z drugimi antihipertenzivi, potrebnimi za doseganje ciljnega krvnega tlaka (glejte poglavja 4.3, 4.4,.4.5 in 5.1).
The demonstration of the benefit of Ziagen is mainly based on results of studies performed in treatment-naïve adult patients on combination therapy with a twice daily regimen (see section 5.1).
Prikaz prednosti zdravila Ziagen v glavnem temelji na rezultatih študij, ki so bile pri režimu odmerjanja dvakrat na dan izvedene pri odraslih bolnikih, ki še niso bili zdravljeni s kombinirano terapijo (glejte poglavje 5.1).
The denominator for relapse is the number of patients with HCV RNA < LLOQ at their last on-treatment assessment.
Denominator za relaps je število bolnikov z HCV RNK < LLOQ ob zadnji oceni med zdravljenjem.
The denominator for relapse is the number of patients with HCV RNA < LLOQ at their last on-treatment assessment.
Denominator za relaps je število bolnikov z RNA HCV < LLOQ ob zadnji oceni med zdravljenjem.
The denominator for relapse is the number of subjects with HCV RNA <LLOQ at their last on-treatment assessment.
Denominator za relaps je število oseb z RNA HCV < LLOQ ob zadnji oceni med zdravljenjem.
The descriptions included below are based on the safety population of 870 patients who received at least 1 dose of bosutinib in either a Phase 3 study in newly diagnosed Ph+ CP CML or in single-arm Phase 1/2 clinical studies that enrolled patients who were resistant or intolerant to prior therapy with Ph+ chronic, accelerated, or blast phase CML, or Ph+ ALL.
Opisi, ki so vključeni spodaj, temeljijo na populaciji 870 bolnikov, ki so prejeli vsaj 1 odmerek bosutiniba bodisi v študiji 3. faze pri bolnikih z novo odkrito Ph+ KML v kronični fazi bodisi v študijah 1./2. faze z eno skupino, v katerih so bili vključeni bolniki s Ph+ KML v kronični, pospešeni ali blastni fazi ali s Ph+ akutno limfoblastno levkemijo (ALL), ki so bili neodzivni ali pa niso prenašali predhodnega zdravljenja.
The desiccant is a moisture absorbing material filled in a small container to protect the tablets from moisture.
Majhen vsebnik vsebuje sušilno sredstvo, ki veže vodo in ščiti tablete pred vlago.
The desiccant sachet should be thrown away and it should not be eaten or inhaled.
Vrečko s sušilom je treba zavreči in se je ne sme zaužiti ali vdihniti.
The design of the study does not allow for
Oblika študije ne omogoča natančne ocene
The design of this study does not allow estimating the risk of MCI progression to clinical AD.
Zasnova te študije ne omogoča ocene tveganja za napredovanje blage kognitivne okvare v klinično AB.
The desired blood glucose levels and the insulin dose regimen must be determined individually and adjusted to suit the patient's diet, physical activity and life-style.
Želeno koncentracijo glukoze v krvi in odmerjanje insulina je treba določiti individualno in ju prilagoditi tako, da ustrezata bolnikovi prehrani, telesni dejavnosti in življenjskemu slogu.
The desired blood glucose levels and the insulin dose regimen must be determined individually and adjusted to suit the patient’s diet, physical activity and life-style.
Želeno koncentracijo glukoze v krvi in shemo odmerjanja insulina je treba določiti individualno in ju prilagoditi tako, da ustrezata bolnikovi prehrani, telesni dejavnosti in življenjskemu slogu.
The desired blood glucose levels, the insulin preparations to be used and the insulin dose regimen (doses and timings) must be determined individually and adjusted to suit the patient’s diet, physical activity and life-style.
Želeno koncentracijo glukoze v krvi, ustrezni pripravek insulina in njegovo odmerjanje (odmerke in čas uporabe) je treba določiti individualno in jih prilagoditi tako, da ustrezajo bolnikovi prehrani, telesni dejavnosti in življenjskemu slogu.
The desired blood glucose levels, the insulin preparations to be used and the insulin dose regimen (doses and timings) must be determined individually and adjusted to suit the patient’s diet, physical activity and life-style.
Želeno koncentracijo glukoze v krvi, ustrezni pripravek insulina in shemo njegovega odmerjanja (odmerke in čas uporabe) je treba določiti individualno in jih prilagoditi tako, da ustrezajo bolnikovi prehrani, telesni dejavnosti in življenjskemu slogu.
The desired blood glucose levels, the insulin preparations to be used and the insulin dose regimen (doses and timings) must be determined individually and adjusted to suit the patient’s diet, physical activity and life-style.
Želeno koncentracijo glukoze v krvi, ustrezni pripravek insulina in shemo njegovega odmerjanje (odmerke in čas uporabe) je treba določiti individualno in jih prilagoditi tako, da ustrezajo bolnikovi prehrani, telesni dejavnosti in življenjskemu slogu.
The desired blood glucose levels, the type of Insuman to be used, and the dose and timing of injections are determined by the doctor for each patient individually, and are adjusted to suit the patient’s diet, physical activity and lifestyle.
Zdravnik za vsakega posameznika posebej določi zaželene koncentracije glukoze v krvi, vrsto zdravila Insuman, ki ga je treba uporabiti ter odmerek in čas uporabe injekcij ter jih prilagodi, da najbolje ustrezajo prehrani, telesni aktivnosti in življenjskemu slogu bolnika.
The desired dose may be withdrawn from the vial by inverting the vial and slowly pulling back on the syringe plunger (Figure 3).
Želeni odmerek lahko iz viale odmerite tako, da vialo obrnete in počasi potegnete bat brizge navzdol (slika 3).
The desired factor X rise is the difference between the patient’s plasma factor X level and the desired level, and based on the observed recovery of 2 IU/dL per IU/kg.
Želeni dvig faktorja X je razlika med ravnjo faktorja X v bolnikovi plazmi in želeno ravnjo ter temelji na opaženem povečanju aktivnosti pri 2 i.e./dl na i.e./kg.
The desired haemoglobin concentration level in two studies was > 13 g/dl (8.1 mmol/l); in the remaining three studies it was 12 to 14 g/dl (7.5 to 8.7 mmol/l).
V dveh študijah je bila želena raven koncentracije hemoglobina > 13 g/dl (8,1 mmol/l), v preostalih dveh pa 12 do 14 g/dl (7,5 do 8,7 mmol/l).
The desired haemoglobin concentration range was 9.6 to
Želeni razpon koncentracije hemoglobina je bil 9,6 do
The desired volume of the dispersion can be drawn into a syringe any time up to six hours after reconstitution.
Potreben volumen disperzije lahko odvzamemo z injekcijsko brizgo kadarkoli v času do šest ur po pripravi.
The detailed operating instructions about the implantable pump, its functions and the necessary safety precautions are described in the Physician’s Manual accompanying the infusion pump.
Podrobna navodila za uporabo implantabilne črpalke, njenih funkcijah in potrebnih previdnostnih ukrepih glede varnosti so opisana v priročniku za zdravnika, priloženemu infuzijski črpalki.
The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion.
Na hitro izločanje presnovkov kaže dejstvo, da so presnovke matične spojine odkrili v urinu in blatu, v plazmi pa ne.
The deterioration in Quality of Life and WHO performance status was significantly less in ibandronic acid treated patients compared with placebo.
Poslabšanje kakovosti življenja in stanja telesne zmogljivosti po klasifikaciji Svetovne zdravstvene organizacije (SZO) je bilo pri bolnikih, zdravljenih z ibandronsko kislino, pomembno manjše v primerjavi z bolniki, ki so dobivali placebo.
The deterioration in Quality of Life was significantly less in Bondronat treated patients compared with placebo.
Poslabšanje kakovosti življenja je bilo pri bolnikih, zdravljenih z zdravilom Bondronat, v primerjavi s placebom značilno manjše.
The determination of 13C/12C-ratio in the carbon dioxide of the breath samples is carried out directly in the breath.
Razmerje med 13C in 12C v ogljikovem dioksidu se določa neposredno v izdihanem zraku.
The determination of a patient’s ABO and Rh blood type are not impacted.
Prisotnost zdravila ne vpliva na določanje krvne skupine sistemov ABO in Rh.
The determination of a patient’s ABO and Rh blood type are not impacted;
Prisotnost zdravila ne vpliva na določanje krvne skupine sistemov ABO in Rh.
The development of a positive direct antiglobulin test (DAGT) may occur during treatment with ceftolozane/tazobactam.
Med zdravljenjem s ceftolozanom/tazobaktamom lahko pride do pozitivnega direktnega antiglobulinskega testa (DAGT - direct antiglobulin test).
The development of a potentially life-threatening serotonin syndrome may occur with the concomitant use of serotonergic drugs such as Selective Serotonin Re-uptake Inhibitors (SSRIs) and Serotonin Norepinephrine Re-uptake Inhibitors (SNRIs), and with drugs which impair metabolism of serotonin (including Monoamine Oxidase Inhibitors [MAOIs]).
Pri sočasni uporabi serotonergičnih zdravil, kot so selektivni zaviralci ponovnega privzema serotonina (SSRI, Selective Serotonin Re-uptake Inhibitors) in zaviralci ponovnega privzema serotonina in noradrenalina (SNRI, Serotonin Norepinephrine Re-uptake Inhibitors) ter zdravili, ki vplivajo na presnovo serotonina (vključno z zaviralci monoaminoksidaze [MAOI, Monoamine Oxidase Inhibitors]), se lahko razvije potencialno življenjsko nevaren serotoninski sindrom.
The development of a potentially life-threatening serotonin syndrome may occur with the concomitant use of serotonergic drugs such as Selective Serotonin Re-uptake Inhibitors (SSRIs) and Serotonin Norepinephrine Re-uptake Inhibitors (SNRIs), and with drugs which impair metabolism of serotonin (including Monoamine Oxidase Inhibitors [MAOIs]).
Pri sočasni uporabi serotonergičnih zdravil, kot so selektivni zaviralci ponovnega privzema serotonina (SSRI, Selective Serotonin Re-uptake Inhibitors) in zaviralci ponovnega privzema serotonina in noradrenalina (SNRI, Serotonin Norepinephrine Re-uptake Inhibitors) ter zdravili, ki vplivajo na presnovo serotonino (vključno z zaviralci monoaminoksidaze [MAOI, Monoamine Oxidase Inhibitors]), se lahko razvije potencialno življenjsko nevaren serotoninski sindrom.
The development of a potentially life-threatening serotonin syndrome may occur with the concomitant use of serotonergic drugs such as Selective Serotonin Re-uptake Inhibitors (SSRIs) and Serotonin Norepinephrine Re-uptake Inhibitors (SNRIs), and with drugs which impair metabolism of serotonin (including Monoamine Oxidase Inhibitors [MAOIs]).
Pri sočasni uporabi serotoninergičnih zdravil, kot so selektivni zaviralci ponovnega privzema serotonina (SSRI, Selective Serotonin Re-uptake Inhibitors) in zaviralci ponovnega privzema serotonina in noradrenalina (SNRI, Serotonin Norepinephrine Re-uptake Inhibitors) ter zdravil, ki vplivajo na presnovo serotonina (vključno z zaviralci monoaminooksidaze [MAOI, Monoamine Oxidase Inhibitors]), se lahko razvije potencialno življenjsko nevaren serotoninski sindrom.
The development of a potentially life-threatening serotonin syndrome may occur with the concomitant use of serotonergic medicinal products such as Selective Serotonin Re-uptake Inhibitors (SSRIs) and Serotonin Norepinephrine Re-uptake Inhibitors (SNRIs), and with medicinal products which impair metabolism of serotonin (including Monoamine Oxidase Inhibitors [MAOIs]).
Pri sočasni uporabi serotonergičnih zdravil, kot so selektivni zaviralci ponovnega privzema serotonina (SSRI, Selective Serotonin Re-uptake Inhibitors) in zaviralci ponovnega privzema serotonina in noradrenalina (SNRI, Serotonin Norepinephrine Re-uptake Inhibitors), ter zdravili, ki vplivajo na presnovo serotonina (vključno z zaviralci monoaminoksidaze [MAOI, Monoamine Oxidase Inhibitors]), se lahko razvije potencialno življenjsko nevaren serotoninski sindrom.
The development of antibodies has not been shown to affect clinical efficacy or safety (see section 5.2).
Pokazalo se je, da razvoj protiteles ne vpliva na klinično učinkovitost ali varnost (glejte poglavje 5.2).
The development of auto-antibodies and autoimmune disorders has been reported during treatment with alfa interferons.
Med zdravljenjem z interferoni alfa so poročali o nastanku avtoprotiteles in avtoimunskih boleznih.
The development of hyperglycaemia appears to be related to decreases in secretion of insulin (particularly in the post-dose period) and of incretin hormones (i.e. glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]).
Kaže, da je razvoj hiperglikemije povezan z zmanjšanim sproščanjem insulina (zlasti v obdobju po odmerku) in hormonov inkretinov (to sta glukagonu podoben peptid-1 [glucagon-like peptide-1, GLP- 1] in od glukoze odvisni insulinotropni polipeptid [glucose-dependent insulinotropic polypeptide, GIP]).
The device (RebiSmart or RebiSlide) containing a pre-filled cartridge of Rebif must be stored in the device storage box in a refrigerator (2°C – 8°C).
Pripomoček (RebiSmart ali RebiSlide), ki vsebuje napolnjen vložek zdravila Rebif, shranjujte v škatli za pripomoček, v hladilniku (2 °C-8 °C).
The device (RebiSmart or RebiSlide) containing a pre-filled cartridge of Rebif must be stored in the device storage box in a refrigerator (2°C – 8°C).
Pripomočke (RebiSmart ali RebiSlide), ki vsebujejo napolnjen vložek zdravila Rebif, shranjujte v škatli za pripomoček, v hladilniku (2 °C-8 ºC).
The device containing a cartridge of Rebif must be stored in the device storage box in a refrigerator (2°C – 8°C).
Pripomoček, ki vsebuje vložek zdravila Rebif, shranjujte v škatli za pripomoček, v hladilniku (2 °C-8 °C).
The device is a single use pre-filled pen.
Pripomoček je napolnjen injekcijski peresnik za enkratno uporabo.
The device is a single use pre-filled syringe.
Pripomoček je napolnjena injekcijska brizga za enkratno uporabo.
The device must be dry prior to use.
Pripomoček mora biti suh, preden se uporabi.
The devices required for dosing in children up to 20 kg body weight (i.e. medicine cup with graduations at 20, 40, 60, 80 ml; 10 ml and 20 ml oral dosing syringes with graduation at 1 ml divisions) are not included in the Kuvan pack.
Pripomočki, potrebni za odmerjanje pri otrocih s telesno maso do 20 kg (tj. lonček za zdravilo z oznakami za 20, 40, 60, 80 ml; 10 ml in 20 ml peroralne odmerne brizge z oznakami po 1 ml), niso vključeni v pakiranje zdravila Kuvan.